Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832351 | 0.85 | PCSK9 (0.36) | NOS1CYP17A1PCSK9NAMPTMEN1 | |
| SCHEMBL28208378 | 0.84 | ELANE (0.36) | NOS1ELANECYP17A1PCSK9NAMPT | |
| SCHEMBL20591975 | 0.84 | NOS1 (0.44) | NOS1ELANEFBP1PDE4BF2 | |
| SCHEMBL23259297 | 0.83 | TDP1 (0.40) | NOS1PCSK9MEN1GAAKMT2A | |
| SCHEMBL17666147 | 0.82 | FBP1 (0.35) | NOS1ELANECYP17A1PCSK9NAMPT | |
| SCHEMBL126581 | 0.82 | ELANE (0.35) | NOS1ELANECYP17A1PCSK9NAMPT | |
| SCHEMBL22755543 | 0.81 | TDP1 (0.48) | MEN1GAAKMT2A | |
| SCHEMBL22755596 | 0.81 | TDP1 (0.44) | PCSK9MEN1GAAKMT2A | |
| SCHEMBL22755562 | 0.80 | KDM1A (0.43) | NAMPTKMT2AL3MBTL1 | |
| SCHEMBL8199609 | 0.80 | PPARA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036560-A | Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof | 中国医学科学院阜外医院 | 2026-05-15 | — | — | CN | claimed |
| CN-122036560-A | Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof | 中国医学科学院阜外医院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4655289-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | Glyphic Biotechnologies, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | NOOGEN LLC (RU) | 2025-09-16 | — | — | US | disclosed |
| CN-119522092-A | Multivalent molecule-based lipid nanoparticles for nucleic acid delivery | 比奥-特里普公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024159162-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240142876-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| US-20240105451-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2023199881-A1 | METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE AND RESIST UNDERLAYER FILM FORMING COMPOSITION | JSR株式会社 | 2023-10-19 | — | — | WO | disclosed |
| CN-1419546-A | 4, 5-dihydro-1H-pyrazole derivatives having CB 1-antagonistic activity | SOLVAY PHARM BV (NL) | 2003-05-21 | — | — | CN | disclosed |
| US-6476060-B2 | DRUG ABUSE; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS; CARDIOVASCUALR DISORDERS | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2002-11-05 | — | — | US | disclosed |
| EP-1206447-A1 | SELECTIVE INHIBITORS OF THE UROKINASE PLASMINOGENE ACTIVATORS | Wilex Biotechnology GmbH (DE) | 2002-05-22 | — | — | EP | disclosed |
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2001-12-20 | — | — | US | disclosed |
| WO-2001014324-A1 | SELECTIVE INHIBITORS OF THE UROKINASE PLASMINOGENE ACTIVATORS | WILEX AG (DE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000078723-A1 | PROCESS FOR THE PREPARATION OF BUTOXYCARBONYLIMINO COMPOUNDS AND INTERMEDIATES THEREFOR | GLAXO GROUP LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| EP-1037668-A1 | TRANSFECTION PARTICLES | Boehringer Ingelheim International GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| EP-0945138-A1 | Transfection particles | Université Louis Pasteur de Strasbourg (FR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999037667-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999029349-A1 | TRANSFECTION PARTICLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053788-A1 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR1, CNR2, CBR3 | NOS1 3155/4885ELANE 3992/4885CYP17A1 1171/4885 |
| US-12415828-B2 | Modified oligonucleotides and methods for their synthesis | RNGTT, TYMP, POLM | NOS1 4361/4885ELANE 2895/4885CYP17A1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.